Human Resources Your Company / Best Companies / Medicis Pharmaceutical Corporation / Ernst & Young LLP / Nanomi B.V. / Holdings SA / Lupin Limited / Deloitte Haskins & Sells LLP / Lab Grin / Laboratorios Grin S.A. DE C.V. / Yoshindo Inc. / IMS Health / Bloomberg / Units Total / /
Country
Switzerland / Netherlands / Mexico / South Africa / Japan / United States / Canada / Australia / India / /
Currency
USD / /
Event
Business Partnership / FDA Phase / General or Shareholder Meeting / M&A / /
IndustryTerm
manufacturing facility / strategy groups / selected such accounting policies / respiratory products / technology curve / injectable products / energy efficient induction motors / energy saving panel / furnace oil / chemical route / opthalmic pharmaceutical / regarded management / pharmaceutical / adequate accounting records / energy / generic pharmaceutical player / manufacturing teams / therapies for various diseases / pharmaceuticals / energy consumption / energy cost / intellectual property groups / generic pharmaceutical / pharmaceutical research / completed technology transfer / energy saving / technology platforms / diesel oil / quality products / technology absorption / generic products / /
MusicGroup
Board of Directors / /
NaturalFeature
Cu. mt. / /
Organization
Work Institute / Audit Committee / Education and Protection Fund / Central Government / Bioresearch Centre / PER UNIT OF PRODUCTION / FDA / Central Government on Mumbai / European Union / Securities and Exchange Board of India / /
Person
Dileep C. Choksi / R. A. Shah / Vijay Kelkar / Richard Zahn / Kamal K. Sharma / Desh Bandhu Gupta / S. D. Shenoy / K. U. Mada / /
Position
forthcoming Annual General / Company Secretary at the registered office / Cost Accountant / Vice Chairman / General / growing generics player in the US / year Chairman / Chairman / generic pharmaceutical player / Annual General / /
Product
APls / US / /
ProvinceOrState
Maryland / Florida / /
PublishedMedium
The Economic Times / /
Technology
Biotechnology / API / Imported technology / Drug Discovery / XBRL / flash / specific technology / /
Reports and Financials Seven Year Financial Summary............................................................................................ 46